Phase 2Recruiting
Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma (Dragonfly)
- Sponsor
- Anna Raciborska (Academic or other)
- Enrolment
- 40 planned
- Conditions
- Osteosarcoma
- Interventions
- Mifamurtide; Sorafenib
- Ages
- children, adults
- Registry
- NCT07787429
Full record on ClinicalTrials.gov
From the registry
Prospective, open, interventional, randomized, non-commercial trial
Primary outcomes
- Event-Free Survival (EFS)
History
Primary completion expected
Last registry update
Registered
Started